title: Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats.
abstract: Tamoxifen is widely used to treat oestrogen-dependent carcinoma of the breast. Previous long-term studies have shown that oral administration of tamoxifen induces hepatoproliferative lesions and hepatocellular tumours in rats. 4-hydroxytamoxifen is an active metabolite of tamoxifen undergoing clinical evaluation for the treatment of various non-malignant breast diseases by topical application. In the present study, 4-hydroxytamoxifen was administered daily by cutaneous application for 101 weeks to groups of 50 female Sprague-Dawley rats at 20, 140 or 1000 microg/kg/day. The product was applied with no occlusive bandage and oral ingestion was avoided by application of an Elizabethan collar for 6 h after administration. Treatment with 4-hydroxytamoxifen was clinically well tolerated and induced changes such as decreased food consumption and body weight gain, uterine and ovarian atrophy, mucification of vaginal epithelium and reduced mammary development, all of which were attributed to its pharmacological action. Mortality was significantly lower in the treated animals. The number of animals with palpable masses was similarly reduced. The incidence of mammary tumours and hypophyseal tumours was markedly lower in 4-hydroxytamoxifen-treated animals. The incidence of chronic tubulo-interstitial nephropathies, a common cause of mortality, was also lowered. There was no evidence of a carcinogenic action of 4-hydroxytamoxifen on the liver, genital organs or skin. Plasma levels of 4-hydroxytamoxifen were stable over the duration of the study and were proportional to the administered dose, exceeding clinical plasma levels by 60-fold at the high dose-level. In conclusion, 4-hydroxytamoxifen is not carcinogenic in the rat and reduces the incidence of spontaneous mammary and hypophyseal tumours.
authors.affiliation: Centre International de Toxicologie, Evreux, France.
authors.forename: F
authors.initials: F
authors.lastname: Sauvez
authors.forename: D S
authors.initials: DS
authors.lastname: Drouin
authors.forename: M
authors.initials: M
authors.lastname: Attia
authors.forename: H
authors.initials: H
authors.lastname: Bertheux
authors.forename: R
authors.initials: R
authors.lastname: Forster
mesh_terms: D000279:Administration, Cutaneous; D000311:Adrenal Glands / Q000187:drug effects / Q000473:pathology; D000818:Animals; D001772:Blood Cell Count / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000494:pharmacology; D004341:Drug Evaluation; D004435:Eating / Q000187:drug effects; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D005836:Genitalia, Female / Q000187:drug effects / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000401:mortality / Q000517:prevention & control; D010173:Palpation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015996:Survival Rate; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry / Q000494:pharmacology; D013950:Thymus Gland / Q000187:drug effects / Q000473:pathology
chemical_list: D002273:Carcinogens; D004965:Estrogen Antagonists; D013629:Tamoxifen; C016601:afimoxifene